nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

25.11.2017 | Review Article

MRI and multiple sclerosis––the evolving role of MRI in the diagnosis and management of MS: the radiologist’s perspective

verfasst von: Alexis M. Cahalane, Hugh Kearney, Yvonne M. Purcell, Christopher McGuigan, Ronan P. Killeen

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Magnetic resonance imaging (MRI) plays an integral role in the management of multiple sclerosis (MS), from both diagnostic and therapeutic perspectives. This 2-part review aims to detail the evolving and expanding role of MRI for both radiologists and neurologists. In this article, we discuss the diagnostic criteria for MS relevant to radiologists, as well as its varying imaging manifestations. The role of MRI in therapeutic modification and complications are discussed.

Filippi M, Rocca MA (2011) MR imaging of multiple sclerosis. Radiology 259(3):659–681CrossRefPubMed

Wattjes MP, Steenwijk MD, Stangel M (2015) MRI in the diagnosis and monitoring of multiple sclerosis: an update. Clin Neuroradiol 25(Suppl 2):157–165CrossRefPubMed

Ge Y (2006) Multiple sclerosis: the role of MR imaging. AJNR Am J Neuroradiol 27(6):1165–1176PubMed

Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis––the plaque and its pathogenesis. N Engl J Med 354(9):942–955CrossRefPubMed

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRefPubMedPubMedCentral

Cotton F, Weiner HL, Jolesz FA, Guttmann CR (2003) MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 60(4):640–646CrossRefPubMed

Rovira A, Wattjes MP, Tintore M, Tur C, Yousry TA, Sormani MP, De Stefano N, Filippi M, Auger C, Rocca MA, Barkhof F, Fazekas F, Kappos L, Polman C, Miller D, Montalban X (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 11(8):471–482CrossRefPubMed

Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Malhotra A, Newsome SD, Oh J, Reich DS, Richert N, Rammohan K, Khan O, Radue EW, Ford C, Halper J, Li D (2016) Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. AJNR Am J Neuroradiol 37(3):394–401CrossRefPubMed

Wattjes MP, Rovira A, Miller D, Yousry TA, Sormani MP, de Stefano MP, Tintore M, Auger C, Tur C, Filippi M, Rocca MA, Fazekas F, Kappos L, Polman C, Frederik B, Xavier M (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis––establishing disease prognosis and monitoring patients. Nat Rev Neurol 11(10):597–606PubMed

10.

Ali EN, Buckle GJ (2009) Neuroimaging in multiple sclerosis. Neurol Clin 27(1):203–219 ixCrossRefPubMed

11.

Rovira A, Auger C, Alonso J (2013) Magnetic resonance monitoring of lesion evolution in multiple sclerosis. Ther Adv Neurol Disord 6(5):298–310CrossRefPubMedPubMedCentral

12.

van Munster CE, Jonkman LE, Weinstein HC, Uitdehaag BM, Geurts JJ (2015) Gray matter damage in multiple sclerosis: impact on clinical symptoms. Neuroscience 303:446–461CrossRefPubMed

13.

Calabrese M, Filippi M, Gallo P (2010) Cortical lesions in multiple sclerosis. Nat Rev Neurol 6(8):438–444CrossRefPubMed

14.

Calabrese M, Castellaro M (2017) Cortical gray matter MR imaging in multiple sclerosis. Neuroimaging Clin N Am 27(2):301–312CrossRefPubMed

15.

Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128(Pt 11):2705–2712CrossRefPubMed

16.

Peterson JW, Bo L, Mork S, Chang A, Trapp BD (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50(3):389–400CrossRefPubMed

17.

Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, Barachino L, Morra A, Rinaldi L, Romualdi C, Perini P, Battistin L, Gallo P (2007) Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 64(10):1416–1422CrossRefPubMed

18.

Sethi V, Yousry TA, Muhlert N, Ron M, Golay X, Wheeler-Kingshott C, Miller DH, Chard DT (2012) Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. J Neurol Neurosurg Psychiatry 83(9):877–882CrossRefPubMed

19.

Calabrese M, Rocca MA, Atzori M, Mattisi I, Bernardi V, Favaretto A, Barachino L, Romualdi C, Rinaldi L, Perini P, Gallo P, Filippi M (2009) Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 72(15):1330–1336CrossRefPubMed

20.

Nelson F, Datta S, Garcia N, Rozario NL, Perez F, Cutter G, Narayana PA, Wolinsky JS (2011) Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis. Mult Scler (Houndmills, Basingstoke, Engl) 17(9):1122–1129CrossRef

21.

Jonkman LE, Klaver R, Fleysher L, Inglese M, Geurts JJ (2015) Ultra-high-field MRI visualization of cortical multiple sclerosis lesions with T2 and T2*: a postmortem MRI and histopathology study. AJNR Am J Neuroradiol 36(11):2062–2067CrossRefPubMed

22.

Seewann A, Kooi EJ, Roosendaal SD, Pouwels PJ, Wattjes MP, van der Valk P, Barkhof F, Polman CH, Geurts JJ (2012) Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 78(5):302–308CrossRefPubMed

23.

Geurts JJ, Bo L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F (2005) Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 26(3):572–577PubMed

24.

Kilsdonk ID, Jonkman LE, Klaver R, van Veluw SJ, Zwanenburg JJ, Kuijer JP, Pouwels PJ, Twisk JW, Wattjes MP, Luijten PR, Barkhof F, Geurts JJ (2016) Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. Brain 139(Pt 5):1472–1481CrossRefPubMed

25.

Gaitan MI, Shea CD, Evangelou IE, Stone RD, Fenton KM, Bielekova B, Massacesi L, Reich DS (2011) Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 70(1):22–29CrossRefPubMedPubMedCentral

26.

Masdeu JC, Quinto C, Olivera C, Tenner M, Leslie D, Visintainer P (2000) Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology 54(7):1427–1433CrossRefPubMed

27.

Bot JC, Barkhof F, Polman CH, Lycklama A, Nijeholt GJ, de Groot V, Bergers E, Ader HJ, Castelijns JA (2004) Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 62(2):226–233CrossRefPubMed

28.

Bermel RA, Naismith RT (2015) Using MRI to make informed clinical decisions in multiple sclerosis care. Curr Opin Neurol 28(3):244–249CrossRefPubMed

29.

Chen JJ, Carletti F, Young V, McKean D, Quaghebeur G (2016) MRI differential diagnosis of suspected multiple sclerosis. Clin Radiol 71(9):815–827CrossRefPubMed

30.

Tartaglino LM, Friedman DP, Flanders AE, Lublin FD, Knobler RL, Liem M (1995) Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 195(3):725–732CrossRefPubMed

31.

Marques IB, Matias F, Silva ED, Cunha L, Sousa L (2014) Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. J Clin Neurosci 21(4):583–586CrossRefPubMed

32.

Petzold A, Wattjes MP, Costello F, Flores-Rivera J, Fraser CL, Fujihara K, Leavitt J, Marignier R, Paul F, Schippling S, Sindic C, Villoslada P, Weinshenker B, Plant GT (2014) The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol 10(8):447–458CrossRefPubMed

33.

Hickman SJ, Brierley CM, Brex PA, MacManus DG, Scolding NJ, Compston DA, Miller DH (2002) Continuing optic nerve atrophy following optic neuritis: a serial MRI study. Mult Scler (Houndmills, Basingstoke, Engl) 8(4):339–342CrossRef

34.

Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, Morgenthau D, Lapierre Y (2013) Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 40(3):307–323CrossRefPubMed

35.

Cross AH, Naismith RT (2014) Established and novel disease-modifying treatments in multiple sclerosis. J Intern Med 275(4):350–363CrossRefPubMed

36.

Wattjes MP, Barkhof F (2014) Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 27(3):260–270CrossRefPubMed

37.

Bag AK, Cure JK, Chapman PR, Roberson GH, Shah R (2010) JC virus infection of the brain. AJNR Am J Neuroradiol 31(9):1564–1576CrossRefPubMed

38.

Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M (2012) Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 72(5):779–787CrossRefPubMed

39.

Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ (2017) Gadolinium-based contrast agents: a comprehensive risk assessment. J Magn Reson Imaging 46(2):338–353CrossRefPubMed

40.

Beam AS, Moore KG, Gillis SN, Ford KF, Gray T, Steinwinder AH, Graham A (2017) GBCAs and risk for nephrogenic systemic fibrosis: a literature review. Radiol Technol 88(6):583–589PubMed

41.

Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet (Lond, Engl) 356(9234):1000–1001CrossRef

42.

Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR (2011) Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovascular imaging 4(11):1206–1216CrossRefPubMed

43.

Grobner T (2006) Gadolinium––a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108CrossRefPubMed

44.

Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17(9):2359–2362CrossRefPubMed

45.

Ramalho J, Ramalho M (2017) Gadolinium deposition and chronic toxicity. Magn Reson Imaging Clin N Am 25(4):765–778CrossRefPubMed

46.

Beckett KR, Moriarity AK, Langer JM (2015) Safe use of contrast media: what the radiologist needs to know. Radiographics 35(6):1738–1750CrossRefPubMed

47.

McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Paolini MA, Murray DL, Williamson EE, Eckel LJ (2017) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 285(2):546–554CrossRefPubMed

48.

Kanda T, Matsuda M, Oba H, Toyoda K, Furui S (2015) Gadolinium deposition after contrast-enhanced MR imaging. Radiology 277(3):924–925CrossRefPubMed

49.

Splendiani A, Perri M, Marsecano C, Vellucci V, Michelini G, Barile A, Di Cesare E (2017) Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients. Radiol Med. https://doi.org/10.1007/s11547-017-0816-9

50.

European Medicines Agency (2017) EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. European Medicines Agency, London

Titel: MRI and multiple sclerosis––the evolving role of MRI in the diagnosis and management of MS: the radiologist’s perspective
verfasst von: Alexis M. Cahalane
Hugh Kearney
Yvonne M. Purcell
Christopher McGuigan
Ronan P. Killeen
Publikationsdatum: 25.11.2017
Verlag: Springer London
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 3/2018
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-017-1714-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

MRI and multiple sclerosis––the evolving role of MRI in the diagnosis and management of MS: the radiologist’s perspective

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Aciclovir-induced acute kidney injury in patients with ‘suspected viral encephalitis’ encountered on a liaison neurology service

Evaluation of the effectiveness and patients’ contentment with transanal haemorrhoidal artery dearterialisation and mucopexy (THD) for treatment of haemorrhoidal disease: a 6-year study

A prospective pilot study of Dilapan-S compared with Propess for induction of labour at 41+ weeks in nulliparous pregnancy

Outcomes from a community-based hypertension educational programme: the West of Ireland Hypertension study

Suboptimal lipid management before and after ischaemic stroke and TIA—the North Dublin Population Stroke Study

Persons with disability, social deprivation and an emergency medical admission

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin